Allopurinol Improves Heart Function in African Americans With Resistant Hypertension
Status:
Not yet recruiting
Trial end date:
2025-05-30
Target enrollment:
Participant gender:
Summary
African American adults in the United States have the highest prevalence rate of high blood
pressure (hypertension) and heart failure in the world. African Americans with treatment
resistant hypertension have higher levels of the enzyme - xanthine oxidase compared to
Caucasians. This trial will test if administration of the xanthine oxidase inhibitor -
Allopurinol (commonly used in the treatment of gout), given over a period of 8 weeks, will
improve heart function, exercise ability and quality of life in African American Veterans
with resistant hypertension.